JP5253746B2 - Composition for prevention and / or treatment of lifestyle-related diseases - Google Patents
Composition for prevention and / or treatment of lifestyle-related diseases Download PDFInfo
- Publication number
- JP5253746B2 JP5253746B2 JP2007061432A JP2007061432A JP5253746B2 JP 5253746 B2 JP5253746 B2 JP 5253746B2 JP 2007061432 A JP2007061432 A JP 2007061432A JP 2007061432 A JP2007061432 A JP 2007061432A JP 5253746 B2 JP5253746 B2 JP 5253746B2
- Authority
- JP
- Japan
- Prior art keywords
- magnesium
- composition
- pantethine
- group
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title description 41
- 201000010099 disease Diseases 0.000 title description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 9
- 230000002265 prevention Effects 0.000 title description 4
- 235000008975 pantethine Nutrition 0.000 claims description 31
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 claims description 28
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 claims description 28
- 239000011581 pantethine Substances 0.000 claims description 28
- 229960000903 pantethine Drugs 0.000 claims description 28
- 210000002966 serum Anatomy 0.000 claims description 24
- 239000000395 magnesium oxide Substances 0.000 claims description 19
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 19
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 19
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 13
- 239000000347 magnesium hydroxide Substances 0.000 claims description 13
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 13
- 230000037356 lipid metabolism Effects 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000008581 daisaikoto Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 40
- 150000002681 magnesium compounds Chemical class 0.000 description 21
- 230000000694 effects Effects 0.000 description 16
- 235000012000 cholesterol Nutrition 0.000 description 14
- 238000009472 formulation Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- GHOKWGTUZJEAQD-ZETCQYMHSA-N pantothenic acid Natural products OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- -1 troche Substances 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 5
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 229940055726 pantothenic acid Drugs 0.000 description 4
- 235000019161 pantothenic acid Nutrition 0.000 description 4
- 239000011713 pantothenic acid Substances 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 150000002948 pantothenic acids Chemical class 0.000 description 3
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000725101 Clea Species 0.000 description 2
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010033685 Pantothenic acid deficiency Diseases 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 2
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 2
- 229940064321 magnesium oxide 100 mg Drugs 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- 229910052919 magnesium silicate Inorganic materials 0.000 description 2
- 235000019792 magnesium silicate Nutrition 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- JXXCENBLGFBQJM-UHFFFAOYSA-N (3-carboxy-2-hydroxypropyl)-trimethylazanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)CC(O)=O JXXCENBLGFBQJM-UHFFFAOYSA-N 0.000 description 1
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- RWIUTHWKQHRQNP-ZDVGBALWSA-N (9e,12e)-n-(1-phenylethyl)octadeca-9,12-dienamide Chemical compound CCCCC\C=C\C\C=C\CCCCCCCC(=O)NC(C)C1=CC=CC=C1 RWIUTHWKQHRQNP-ZDVGBALWSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- HRQKOYFGHJYEFS-UHFFFAOYSA-N Beta psi-carotene Chemical compound CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C HRQKOYFGHJYEFS-UHFFFAOYSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- BMOVQUBVGICXQN-UHFFFAOYSA-N Clinofibrate Chemical compound C1=CC(OC(C)(CC)C(O)=O)=CC=C1C1(C=2C=CC(OC(C)(CC)C(O)=O)=CC=2)CCCCC1 BMOVQUBVGICXQN-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 1
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- KUEUWHJGRZKESU-UHFFFAOYSA-N Niceritrol Chemical compound C=1C=CN=CC=1C(=O)OCC(COC(=O)C=1C=NC=CC=1)(COC(=O)C=1C=NC=CC=1)COC(=O)C1=CC=CN=C1 KUEUWHJGRZKESU-UHFFFAOYSA-N 0.000 description 1
- VRAHPESAMYMDQI-UHFFFAOYSA-N Nicomol Chemical compound C1CCC(COC(=O)C=2C=NC=CC=2)(COC(=O)C=2C=NC=CC=2)C(O)C1(COC(=O)C=1C=NC=CC=1)COC(=O)C1=CC=CN=C1 VRAHPESAMYMDQI-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 241001127637 Plantago Species 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- JLRNKCZRCMIVKA-UHFFFAOYSA-N Simfibrate Chemical compound C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 JLRNKCZRCMIVKA-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 238000001790 Welch's t-test Methods 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- KNGQILZSJUUYIK-VIFPVBQESA-N [(2R)-4-hydroxy-3,3-dimethyl-1-oxo-1-[[3-oxo-3-(2-sulfanylethylamino)propyl]amino]butan-2-yl] dihydrogen phosphate Chemical compound OCC(C)(C)[C@@H](OP(O)(O)=O)C(=O)NCCC(=O)NCCS KNGQILZSJUUYIK-VIFPVBQESA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 239000011795 alpha-carotene Substances 0.000 description 1
- 235000003903 alpha-carotene Nutrition 0.000 description 1
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229940006423 chondroitin sulfate sodium Drugs 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 229950003072 clinofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229920002824 gallotannin Polymers 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 239000011663 gamma-carotene Substances 0.000 description 1
- 235000000633 gamma-carotene Nutrition 0.000 description 1
- HRQKOYFGHJYEFS-RZWPOVEWSA-N gamma-carotene Natural products C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)/C)\C)(\C=C\C=C(/CC/C=C(\C)/C)\C)/C HRQKOYFGHJYEFS-RZWPOVEWSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 229960002600 icosapent ethyl Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960005436 inositol nicotinate Drugs 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229940026187 magnesium hydroxide 100 mg/ml Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229950008446 melinamide Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 210000004237 neck muscle Anatomy 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 229960000827 niceritrol Drugs 0.000 description 1
- 229950001071 nicomol Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- ZNXZGRMVNNHPCA-UHFFFAOYSA-N pantetheine Chemical compound OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 1
- 229960001495 pravastatin sodium Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 229940026314 red yeast rice Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229960004058 simfibrate Drugs 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、生活習慣病の予防および／または治療用の新規な組成物、より詳しくは、高脂血症予防および／または治療用組成物に関する。 The present invention relates to a novel composition for preventing and / or treating lifestyle-related diseases, and more particularly to a composition for preventing and / or treating hyperlipidemia.
パンテチンは、血清総コレステロール低下作用、血清中性脂肪低下作用、血清ＨＤＬコレステロール増加作用等が知られ、パントテン酸欠乏症の予防および治療、消耗性疾患、甲状腺機能亢進症、妊産婦、授乳婦などのパントテン酸の需要が増大し、食事からの摂取が不十分な際の補給、高脂血症、弛緩性便秘、ストレプトマイシンおよびカナマイシンによる副作用の予防および治療、急・慢性湿疹、血液疾患の血小板数および出血傾向の改善のうち、パントテン酸の欠乏または代謝障害が関与すると推定される場合に用いられている（非特許文献１参照）。
酸化マグネシウムや水酸化マグネシウムなどのマグネシウム化合物の多くは、制酸作用、瀉下作用が知られ、制酸薬や瀉下薬として用いられている（非特許文献２および３参照）。
Pantethine is known to lower serum total cholesterol, lower serum triglyceride, increase serum HDL cholesterol, etc., and to prevent and treat pantothenic acid deficiency, debilitating diseases, hyperthyroidism, pregnant women, and lactating women. Supplementation when demand for acid increases and insufficient intake from the diet, prevention and treatment of side effects caused by hyperlipidemia, flaccid constipation, streptomycin and kanamycin, acute / chronic eczema, platelet count and bleeding in blood disorders It is used when it is estimated that pantothenic acid deficiency or metabolic disorder is involved in the improvement of the trend (see Non-Patent Document 1).
Many magnesium compounds such as magnesium oxide and magnesium hydroxide are known to have antacid action and axillary action, and are used as antacids and axides (see Non-Patent Documents 2 and 3).
本発明は、新規な生活習慣病の予防および／または治療用組成物、より具体的には血清脂質代謝改善用組成物を提供するものである。 The present invention provides a novel composition for preventing and / or treating lifestyle-related diseases, more specifically, a composition for improving serum lipid metabolism.
本発明者らは、鋭意研究を行った結果、パンテチン類とマグネシウム化合物を併用すると、優れた血清総コレステロール低下作用、血清中性脂肪低下作用、血清ｎｏｎＨＤＬコレステロール低下作用を示すことを見出し、パンテチン類およびマグネシウム化合物を含有する組成物が、生活習慣病の予防および／または治療用組成物として有用であることを新たに見出し、本発明を完成した。 As a result of intensive studies, the present inventors have found that when pantetins and a magnesium compound are used in combination, they exhibit excellent serum total cholesterol lowering action, serum neutral fat lowering action, and serum nonHDL cholesterol lowering action. The inventors have newly found that a composition containing a magnesium compound is useful as a composition for preventing and / or treating lifestyle-related diseases, and completed the present invention.
すなわち、本発明はパンテチン類およびマグネシウム化合物を含有する組成物に関するものであり、以下の発明に関する。
（１）パンテチン類、およびマグネシウム化合物を含有する組成物。
（２）１日当たりの投与（服用）量として、パンテチン類を１〜２０００ｍｇ、およびマグネシウム化合物を１００〜１５０００ｍｇ含有する組成物。
（３）パンテチン類がパンテチンである上記（１）または（２）記載の組成物。
（４）マグネシウム化合物が、塩化マグネシウム、酸化マグネシウム、水酸化マグネシウム、硫酸マグネシウム、炭酸マグネシウム、ケイ酸マグネシウムおよびメタケイ酸アルミン酸マグネシウムからなる群より選ばれる１または２以上のである上記（１）〜（３）のいずれか１つに記載の組成物。
（５）パンテチン、および酸化マグネシウムまたは水酸化マグネシウムを含有する組成物。
（６）医薬用である上記（１）〜（５）のいずれか１つに記載の組成物。
（７）食品用である上記（１）〜（５）のいずれか１つに記載の組成物。
（８）生活習慣病の予防および／または治療用である上記（１）〜（５）のいずれか１つに記載の組成物。
（９）血清脂質代謝改善用である上記（１）〜（５）のいずれか１つに記載の組成物。
（１０）剤形が経口投与製剤である上記（１）〜（９）のいずれか１つに記載の組成物。
（１１）剤形が錠剤、カプセル剤、散剤、細粒剤、液剤、トローチ剤、ゼリー剤、舐剤またはシロップ剤である上記（１）〜（９）のいずれか１つに記載の組成物。
That is, the present invention relates to a composition containing panthetins and a magnesium compound, and relates to the following inventions.
(1) A composition containing panthetins and a magnesium compound.
(2) A composition containing 1 to 2000 mg of pantethine and 100 to 15000 mg of a magnesium compound as the amount of administration (dose) per day.
(3) The composition according to (1) or (2) above, wherein the pantethine is pantethine.
(4) The above (1) to (1), wherein the magnesium compound is one or more selected from the group consisting of magnesium chloride, magnesium oxide, magnesium hydroxide, magnesium sulfate, magnesium carbonate, magnesium silicate and magnesium aluminate metasilicate. The composition according to any one of 3).
(5) A composition containing pantethine and magnesium oxide or magnesium hydroxide.
(6) The composition according to any one of (1) to (5), wherein the composition is for pharmaceutical use.
(7) The composition according to any one of (1) to (5), which is for food.
(8) The composition according to any one of (1) to (5) above, which is used for prevention and / or treatment of lifestyle-related diseases.
(9) The composition according to any one of (1) to (5), which is used for improving serum lipid metabolism.
(10) The composition according to any one of (1) to (9) above, wherein the dosage form is an orally administered preparation.
(11) The composition according to any one of (1) to (9) above, wherein the dosage form is a tablet, capsule, powder, fine granule, solution, troche, jelly, electuary or syrup .
後記実施例から明らかなように、パンテチン類とマグネシウム化合物を併用すると、優れた血清総コレステロール低下作用、血清中性脂肪低下作用、血清ｎｏｎＨＤＬコレステロール低下作用、すなわち血清脂質代謝改善作用を示した。したがって、パンテチン類およびマグネシウム化合物を含有する組成物は、生活習慣病の予防および／または治療用組成物として有用であり、このものは医薬または食品として利用することができ、有用なものである。 As will be apparent from the examples described later, when pantethines and a magnesium compound were used in combination, an excellent serum total cholesterol lowering effect, serum neutral fat lowering effect, serum nonHDL cholesterol lowering effect, that is, serum lipid metabolism improving effect was exhibited. Therefore, a composition containing panthetins and a magnesium compound is useful as a composition for preventing and / or treating lifestyle-related diseases, and it can be used as a medicine or food and is useful.
本発明にかかるパンテチン類は、公知の化合物であり、その入手方法としては、市販品を用いてもよく、また公知の方法に基づき製造することもできる。パンテチン類としては、パントテニルアルコール、パントテニルエチルエーテル、アセチルパントテニルエチルエーテル、ベンゾイルパントテニルエチルエーテル、ジカルボエトキシパントテン酸エチルエステル、パンテテイン、パンテチン、ホスホパンテテイン、パントテン酸、パントテン酸の塩などを挙げることができる。パントテン酸の塩としては、塩酸塩、硝酸塩、硫酸塩等の鉱酸塩、ナトリウム塩、カリウム塩、カルシウム塩、マグネシウム塩等のアルカリ金属塩、アルカリ土類金属塩等を挙げることができる。本発明において、パンテチン類としては、パンテチン、パントテン酸、パントテン酸の塩が好ましく、パントテン酸の塩としては、パントテン酸カルシウムが好ましい。 The pantethine according to the present invention is a known compound, and as a method for obtaining it, a commercially available product may be used, or it can be produced based on a known method. Panthetins include pantothenyl alcohol, pantothenyl ethyl ether, acetyl pantothenyl ethyl ether, benzoyl pantothenyl ethyl ether, dicarboethoxy pantothenic acid ethyl ester, pantethein, panthetin, phosphopantethein, pantothenic acid, pantothenic acid salt, etc. Can be mentioned. Examples of the salt of pantothenic acid include mineral salts such as hydrochloride, nitrate and sulfate, alkali metal salts such as sodium salt, potassium salt, calcium salt and magnesium salt, and alkaline earth metal salt. In the present invention, pantethins, pantothenic acid, and pantothenic acid salts are preferred as pantetins, and calcium pantothenate is preferred as the pantothenic acid salt.
本発明にかかるマグネシウム化合物は、公知の化合物であり、その入手方法としては、市販品を用いてもよく、また公知の方法に基づき製造することもできる。マグネシウム化合物としては、塩化マグネシウム、酸化マグネシウム、水酸化マグネシウム、硫酸マグネシウム、炭酸マグネシウム、ケイ酸マグネシウムやメタケイ酸アルミン酸マグネシウムなどを挙げることができる。本発明において、マグネシウム化合物としては、酸化マグネシウム、水酸化マグネシウムが好ましい。 The magnesium compound according to the present invention is a known compound, and as a method for obtaining it, a commercially available product may be used, or it can be produced based on a known method. Examples of the magnesium compound include magnesium chloride, magnesium oxide, magnesium hydroxide, magnesium sulfate, magnesium carbonate, magnesium silicate and magnesium aluminate metasilicate. In the present invention, the magnesium compound is preferably magnesium oxide or magnesium hydroxide.
本発明の組成物には、本発明にかかるパンテチン類およびマグネシウム化合物以外に、さらに以下に示す成分を配合してもよい。配合可能な成分としては、プラバスタチンナトリウム、シンバスタチン、アトルバスタチンカルシウム水和物などのＨＭＧ−ＣｏＡ還元酵素阻害剤、ベザフィブラート、クロフィブラート、シンフィブラート、イコサペント酸エチル、ポリエンホスファチジルイコリン、デキストラン硫酸ナトリウム、γ−オリザノール、ニコモール、ニセリトロール、クリノフィブラート、コレスチラミン、エラスターゼＥＳ、メリナミド、プロブコールやＤＰＡ（ドコサペンタエン酸）、ＤＨＡ（ドコサヘキサエン酸）、ＥＰＡ（エイコサペンタエン酸）、γ−リノレン酸、リノール酸、異性化リノール酸などの脂肪酸類、デキストリン、ポリデキストロース、アルギン酸、アルギン酸ナトリウム、キチン、キトサン、セルロース、ヘミセルロース、リグニン、マンナン、カルボキシメチルセルロース、カラギナンなどの食物繊維類、リコペン、アスタキサンチン、α−カロテン、β−カロテン、γ−カロテン、ルテイン、ゼアキサンチン、クリプトキサンチンなどのカロチノイド類、コンドロイチン硫酸、コンドロイチン硫酸ナトリウム、フコイダンなどのムコ多糖、レシチン、ホスファチジルコリン、ホスファチジルイノシトールなどのリン脂質、大豆タンパク質、タウリン、メチオニン、アルギニン、シテインなどのタンパク・アミノ酸、ビール酵母、紅麹などの菌・酵母、ヘスペリジン、ナリンゲニン、ルチン、ケルセチン、プロアントシアニジン、カテキン、ガロタンニン、ダイゼイン、ゲニスチンなどのポリフェノール類、アスコルビン酸、ニコチン酸、ニコチン酸アミド、葉酸、トコトリエノール、トコフェロール、リボフラビン、ピリドキシンなどのビタミン類、Ｌ−カルニチン、ｄｌ−塩化カルニチン、酒石酸水素コリン、イノシトール、コエンザイムＱ１０などのビタミン類似成分、イノシトールヘキサニコチネート、ヘプロニカート、ニコチン酸トコフェロールなどのビタミン誘導体、プラセンタエキスなどの動物由来成分、スピルリナ、ニンニク、月見草油、ブルーベリー、イチョウ葉、ショウキョウ、セイヨウサンザシ、カシュウ、トチュウ、シゴカ、人参、クコシ、ウコン、レイシ、田七人参、プランタゴ オバタなどのハーブ・生薬およびこれらの抽出物等を挙げることができるが、上記のもののみに限定されるべきものではない。これらの成分は、単一成分を配合してもよく、２種以上のものを組み合わせて配合してもよい。 In addition to the pantethines and magnesium compounds according to the present invention, the following components may be further blended in the composition of the present invention. Ingredients that can be added include HMG-CoA reductase inhibitors such as pravastatin sodium, simvastatin, atorvastatin calcium hydrate, bezafibrate, clofibrate, simfibrate, ethyl icosapentate, polyenephosphatidylcholine, dextran sulfate sodium, γ- Oryzanol, nicomol, niceritrol, clinofibrate, cholestyramine, elastase ES, melinamide, probucol, DPA (docosapentaenoic acid), DHA (docosahexaenoic acid), EPA (eicosapentaenoic acid), γ-linolenic acid, linoleic acid, isomerism Fatty acids such as linoleic acid, dextrin, polydextrose, alginic acid, sodium alginate, chitin, chitosan, cellulose, hemicellulose, ligni Dietary fibers such as chloroquine, mannan, carboxymethylcellulose, carrageenan, lycopene, astaxanthin, α-carotene, β-carotene, γ-carotene, lutein, zeaxanthin, cryptoxanthine and other carotenoids, chondroitin sulfate, chondroitin sulfate sodium, fucoidan, etc. Phospholipids such as mucopolysaccharide, lecithin, phosphatidylcholine, phosphatidylinositol, proteins and amino acids such as soy protein, taurine, methionine, arginine, cytein, fungi and yeast such as brewer's yeast, red yeast rice, hesperidin, naringenin, rutin, quercetin, Polyphenols such as proanthocyanidins, catechins, gallotannins, daidzein, genistin, ascorbic acid, nicotinic acid, nicotinamide, folic acid, toco Rienoru, vitamins tocopherol, riboflavin, etc. pyridoxine, L- carnitine, dl-carnitine chloride, choline bitartrate, inositol, vitamin similar components such as coenzyme Q 10, inositol hexanicotinate, Hepuronikato, vitamin derivatives such as tocopherol nicotinate , Animal ingredients such as placenta extract, herbs such as spirulina, garlic, evening primrose oil, blueberry, ginkgo biloba, ginger, hawthorn, kashi, eucommia, staghorn, carrot, kokushi, turmeric, litchi, ginseng, plantago obata -Herbal medicines and extracts thereof can be mentioned, but should not be limited to the above. These components may be blended as a single component or in combination of two or more.
本発明の組成物は、経口的、非経口的に投与することができるが、経口的に投与することが好ましい。経口的に投与する製剤としては、錠剤、カプセル剤、散剤、細粒剤、液剤、トローチ剤、ゼリー剤、舐剤、シロップ剤等を挙げることができる。本発明の組成物は、医薬、飲料や固形物などの食品として用いることができる。 The composition of the present invention can be administered orally or parenterally, but is preferably administered orally. Examples of the preparation to be administered orally include tablets, capsules, powders, fine granules, solutions, troches, jellies, electuaries and syrups. The composition of this invention can be used as foodstuffs, such as a pharmaceutical, a drink, and a solid substance.
製剤化は、公知の製剤技術により行うことができ、製剤中には適当な製剤添加物を加えることができる。製剤添加物は、本発明の効果を損なわない範囲で適宜加えればよい。製剤添加物としては、賦形剤、結合剤、崩壊剤、流動化剤、乳化剤、安定化剤等を挙げることができる。 Formulation can be performed by known formulation techniques, and appropriate formulation additives can be added to the formulation. What is necessary is just to add a formulation additive suitably in the range which does not impair the effect of this invention. Examples of the formulation additive include an excipient, a binder, a disintegrant, a fluidizer, an emulsifier, and a stabilizer.
本発明の組成物における、パンテチン類、およびマグネシウム化合物の配合比は、パンテチン類：マグネシウム化合物が１：０．０１〜１：１００が好ましく、１：０．１〜１：１０がさらに好ましい。 The compounding ratio of panthetins and magnesium compounds in the composition of the present invention is preferably 1: 0.01 to 1: 100, more preferably 1: 0.1 to 1:10 for panthetines: magnesium compounds.
本発明の組成物の投与（配合）量は、性別、年齢、症状、投与方法、投与回数、投与時期等により適宜検討を行い、適当な投与（配合）量を決めればよい。例えば、経口投与の場合、パンテチン類については、１日当たり１〜２０００ｍｇ投与（配合）することが好ましく、５〜１０００ｍｇ投与（配合）することがさらに好ましい。マグネシウム化合物については、１日当たり１００〜１５０００ｍｇ投与（配合）することが好ましく、４００〜２０００ｍｇ投与（配合）することがさらに好ましい。 The administration (formulation) amount of the composition of the present invention may be appropriately determined according to sex, age, symptoms, administration method, number of administrations, administration timing, etc., and an appropriate administration (composition) amount may be determined. For example, in the case of oral administration, pantetins are preferably administered (mixed) at 1 to 2000 mg per day, and more preferably 5 to 1000 mg (mixed). The magnesium compound is preferably administered (mixed) at 100 to 15000 mg per day, and more preferably 400 to 2000 mg (mixed).
本発明の組成物は、本発明にかかる全成分を含む単一の製剤として製し、これを投与（服用）してもよいし、また本発明に係る各成分を分けて別の製剤とし、それら製剤を同時または順次投与（服用）可能としたキット製剤としてもよい。 The composition of the present invention is manufactured as a single preparation containing all the components according to the present invention and may be administered (taken), or each component according to the present invention is divided into separate preparations, These preparations may be kit preparations that can be administered simultaneously or sequentially (taken).
本発明の組成物は、優れた血清脂質代謝改善作用（血清総コレステロール低下作用、血清中性脂肪低下作用、血清ｎｏｎＨＤＬコレステロール低下作用）を示すことから、生活習慣病の予防および／または治療に有用である。本発明の組成物の効能・効果、適応症としては、具体的には、高脂血症、糖尿病、肥満、心筋梗塞、動脈硬化症、脳梗塞、脳卒中、狭心症、高コレステロールに伴う諸症状の改善：頭痛、頭重、肩・首筋のこり、手足のしびれ・冷え、レイノー症候群などを挙げることができる。 The composition of the present invention exhibits an excellent effect of improving serum lipid metabolism (serum total cholesterol lowering action, serum triglyceride lowering action, serum nonHDL cholesterol lowering action), and thus is useful for prevention and / or treatment of lifestyle-related diseases. It is. Specifically, the efficacy, effect and indication of the composition of the present invention include hyperlipidemia, diabetes, obesity, myocardial infarction, arteriosclerosis, cerebral infarction, stroke, angina pectoris, and high cholesterol. Symptom improvement: Headache, head weight, stiff shoulders / neck muscles, numbness / coldness of limbs, Raynaud's syndrome.
以下に、実施例を示して本発明を説明するが、本発明はこれらにのみ限定されるべきものではない。 Hereinafter, the present invention will be described with reference to examples. However, the present invention should not be limited to these examples.
１．血清脂質に対する作用
（１）動物
３週齢の雄性Ｓｌｃ：Ｓｙｒｉａｎハムスター（日本エスエルシー株式会社）をＦ２飼料（日本クレア株式会社）で約１週間予備飼育した後、Ｑｕｉｃｋ Ｆａｔ飼料（日本クレア株式会社）に切り替え、２週間の高脂肪食負荷を行った。なお、正常食群はそのままＦ２飼料を与えた。
1. Action on Serum Lipid (1) Animal After three weeks old male Slc: Syrian hamster (Japan SLC Co., Ltd.) was preliminarily raised with F2 feed (Clea Japan Co., Ltd.) for about 1 week, Quick Fat diet (Clea Japan Co., Ltd.) ) And a high fat diet load for 2 weeks. The normal diet group was fed with F2 feed as it was.
（２）投与検体の調製法
（イ）媒体
０．５％メチルセルロース（ＭＣ）溶液（和光純薬工業株式会社）を使用した。
（ロ）パンテチン１２０ｍｇ/ｍＬ液
８０％パンテチン液を１５０ｍｇ/ｍＬになるように上記媒体で溶解した。
（ハ）酸化マグネシウム１００ｍｇ/ｍＬ溶液
必要量の酸化マグネシウムを秤量し、上記媒体で、１００ｍｇ/ｍＬ溶液になるように溶解した。
（ニ）パンテチン１２０ｍｇ/ｍＬ＋酸化マグネシウム１００ｍｇ/ｍＬ溶液
まず、２倍量のパンテチン２４０ｍｇ/ｍＬ溶液を作製した。次に必要量の酸化マグネシウムにパンテチン２４０ｍｇ/ｍＬ溶液と０．５％ＭＣ溶液を等量ずつ加え酸化マグネシウムの濃度が１００ｍｇ/ｍＬになるようにした。
（ホ）パンテチン１２０ｍｇ/ｍＬ＋水酸化マグネシウム１００ｍｇ/ｍＬ溶液
まず、２倍量のパンテチン２４０ｍｇ/ｍＬ溶液を作製した。次に必要量の水酸化マグネシウムにパンテチン２４０ｍｇ/ｍＬ溶液と０．５％ＭＣ溶液を等量ずつ加え水酸化マグネシウムの濃度が１００ｍｇ/ｍＬになるようにした。
(2) Preparation method of administration specimen (a) Medium A 0.5% methylcellulose (MC) solution (Wako Pure Chemical Industries, Ltd.) was used.
(B) Pantethine 120 mg / mL solution An 80% pantethine solution was dissolved in the above medium to a concentration of 150 mg / mL.
(C) Magnesium oxide 100 mg / mL solution A required amount of magnesium oxide was weighed and dissolved in the above medium so as to be a 100 mg / mL solution.
(D) Pantethine 120 mg / mL + magnesium oxide 100 mg / mL solution First, a double amount of pantethine 240 mg / mL solution was prepared. Next, an equivalent amount of a pantethine 240 mg / mL solution and a 0.5% MC solution were added to the required amount of magnesium oxide so that the concentration of magnesium oxide was 100 mg / mL.
(E) Pantethine 120 mg / mL + magnesium hydroxide 100 mg / mL solution First, a double amount of pantethine 240 mg / mL solution was prepared. Next, pantethine 240 mg / mL solution and 0.5% MC solution were added in equal amounts to the required amount of magnesium hydroxide so that the magnesium hydroxide concentration was 100 mg / mL.
（３）試験法
２週間の高脂肪食負荷の後、１群８匹に分け１日１回連続９日間、上記検体を５ｍＬ/ｋｇハムスターに経口投与し、各薬剤の投与量が表１になるようにした。なお、正常食群、コントロール群は媒体を投与した。
(3) Test method After the high-fat diet load for 2 weeks, the above specimens were orally administered to 5 mL / kg hamster once a day for 9 consecutive days, divided into 8 animals per group. It was made to become. In the normal diet group and the control group, the vehicle was administered.
採血は投与開始前日、投与６日目及び投与９日目の計３回行い、遠心分離（３０００ｒｐｍ、１５分間、４℃）により得られた血清について酵素法を用いて総コレステロール濃度（ｍｇ/ｄＬ）および中性脂肪濃度（ｍｇ/ｄＬ）を測定した。ｎｏｎＨＤＬコレステロール濃度（ｍｇ/ｄＬ）は、沈殿法により得られたＨＤＬ画分中のコレステロール濃度を酵素法で求め、総コレステロール濃度からＨＤＬコレステロール濃度を差し引いて求めた。 Blood was collected a total of three times on the day before the start of administration, the sixth day of administration, and the ninth day of administration, and the serum obtained by centrifugation (3000 rpm, 15 minutes, 4 ° C.) was used to measure the total cholesterol concentration (mg / dL) ) And triglyceride concentration (mg / dL). The nonHDL cholesterol concentration (mg / dL) was determined by determining the cholesterol concentration in the HDL fraction obtained by the precipitation method by an enzymatic method and subtracting the HDL cholesterol concentration from the total cholesterol concentration.
結果を表２〜４に示した。なお、有意差検定は、各時点についてコントロール群と薬物投与群の比較（コントロール群 ｖｓ. パンテチン投与群、酸化マグネシウム投与群、パンテチン＋酸化マグネシウム併用群、パンテチン＋水酸化マグネシウム併用群）およびパンテチン＋酸化マグネシウム併用群と各単独群の比較（ｖｓ.パンテチン投与群、酸化マグネシウム投与群）およびパンテチン＋水酸化マグネシウム投与群とパンテチン投与群の比較およびパンテチンと併用するマグネシウム化合物の違いによる比較（パンテチン＋酸化マグネシウム併用群 ｖｓ. パンテチン＋水酸化マグネシウム併用群）の２群間比較を実施した。すなわち、等分散性をＦ検定で有意水準５％で行い、有意であればＡｓｐｉｎ−Ｗｅｌｃｈのｔ検定を、有意でなければＳｔｕｄｅｎｔのｔ検定を行った。 The results are shown in Tables 2-4. In addition, the significant difference test was performed by comparing the control group and the drug administration group at each time point (control group vs. pantethine administration group, magnesium oxide administration group, pantethine + magnesium oxide combination group, pantetin + magnesium hydroxide combination group) and pantetin + Comparison between magnesium oxide combination group and each single group (vs. pantethine administration group, magnesium oxide administration group), comparison between pantethine + magnesium hydroxide administration group and pantethine administration group, and comparison by difference in magnesium compound used together with pantethine (pantethine + Comparison between two groups of the magnesium oxide combination group vs. pantethine + magnesium hydroxide combination group) was performed. That is, the equidispersity was F-tested at a significance level of 5%. If significant, Aspin-Welch t-test was performed, and if not significant, Student t-test was performed.
＊＊ ｐ＜０．０１、＊＊＊ ｐ＜０．００１ コントロール群に対して有意差あり
＃ ｐ＜０．０５、＃＃ ｐ＜０．０１、＃＃＃ ｐ＜０．００１ パンテチン投与群に対して有意差あり
＄ ｐ＜０．０５、＄＄ ｐ＜０．０１ 酸化マグネシウム投与群に対して有意差あり
結果から明らかなように、高脂肪食摂取（コントロール群）により総コレステロール、中性脂肪およびｎｏｎＨＤＬコレステロール濃度が上昇した。パンテチンおよび酸化マグネシウムまたは水酸化マグネシウムを併用した群（パンテチン＋酸化マグネシウム併用群、パンテチン＋水酸化マグネシウム併用群）は、コントロール群と比べ総コレステロール、中性脂肪及びｎｏｎＨＤＬコレステロール濃度低下作用を示し、パンテチン投与群よりも低下作用が顕著だった。パンテチンおよび酸化マグネシウムを併用した群については、酸化マグネシウム投与群に対しても低下作用が顕著であった。パンテチンと併用するマグネシウム化合物の違いによる効果の差は見られなかった。
したがって、パンテチン類およびマグネシウム化合物を併用すると、優れた血清脂質代謝改善作用を示すことがわかった。
** p <0.01, *** p <0.001 Significantly different from control group
# P <0.05, ## p < 0.01, a significant difference with respect to ### p <0.001 pantethine administration group
$ P <0.05, $$ p <0.01 Significantly different from the magnesium oxide administration group As can be seen from the results, total cholesterol, triglyceride and nonHDL cholesterol levels by high fat diet intake (control group) Rose. The group in which pantethine and magnesium oxide or magnesium hydroxide were used in combination (pantethine + magnesium oxide combination group, pantethine + magnesium hydroxide combination group) showed an effect of lowering total cholesterol, neutral fat and non-HDL cholesterol concentrations compared to the control group. The lowering effect was more remarkable than that of the administration group. In the group in which pantethine and magnesium oxide were used in combination, the lowering effect was significant compared to the magnesium oxide administration group. There was no difference in effect due to the difference in the magnesium compound used in combination with panthetin.
Therefore, it was found that when pantethines and a magnesium compound were used in combination, an excellent effect of improving serum lipid metabolism was exhibited.
本発明のパンテチン類とマグネシウム化合物を含有する組成物は、優れた血清総コレステロール低下作用、血清中性脂肪低下作用、血清ｎｏｎＨＤＬコレステロール低下作用、すなわち血清脂質代謝改善作用を示した。したがって、パンテチン類およびマグネシウム化合物を含有する組成物は、脂質代謝が関わる生活習慣病の予防および／または治療用組成物として有用であり、このものは医薬または食品として利用することができる。 The composition containing panthetins and a magnesium compound of the present invention showed excellent serum total cholesterol lowering effect, serum neutral fat lowering effect, serum nonHDL cholesterol lowering effect, that is, serum lipid metabolism improving action. Therefore, a composition containing panthetins and a magnesium compound is useful as a composition for preventing and / or treating lifestyle-related diseases involving lipid metabolism, and can be used as a medicine or food.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007061432A JP5253746B2 (en) | 2006-03-31 | 2007-03-12 | Composition for prevention and / or treatment of lifestyle-related diseases |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006096770 | 2006-03-31 | ||
| JP2006096770 | 2006-03-31 | ||
| JP2007061432A JP5253746B2 (en) | 2006-03-31 | 2007-03-12 | Composition for prevention and / or treatment of lifestyle-related diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007291068A JP2007291068A (en) | 2007-11-08 |
| JP5253746B2 true JP5253746B2 (en) | 2013-07-31 |
Family
ID=38762054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007061432A Active JP5253746B2 (en) | 2006-03-31 | 2007-03-12 | Composition for prevention and / or treatment of lifestyle-related diseases |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5253746B2 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5581855A (en) * | 1978-12-14 | 1980-06-20 | Dai Ichi Seiyaku Co Ltd | Adduct of pantethine with metal salt |
| JP5065570B2 (en) * | 2002-09-06 | 2012-11-07 | 第一三共ヘルスケア株式会社 | Vascular endothelial nitric oxide synthesis promoter |
| JP2005187454A (en) * | 2003-12-05 | 2005-07-14 | Sankyo Co Ltd | Vitamin e-containing, ldl-reducing agent and/or arteriosclelosis inhibitor composition |
-
2007
- 2007-03-12 JP JP2007061432A patent/JP5253746B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007291068A (en) | 2007-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6368306B2 (en) | Nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease (IBD) | |
| JP5830030B2 (en) | Low calorie high protein nutritional composition for stimulating muscle protein synthesis | |
| EP2689782B1 (en) | Improving memory in subjects with mini-mental state examination of 24-26 | |
| EP2241196B2 (en) | Nutritional supplement comprising oligosaccharides and cysteine for treating hiv | |
| JP2023100869A (en) | Method for improving mitophagy in subject | |
| JP2017506651A (en) | Compositions and methods for reduction or prevention of fatty liver | |
| US20050233944A1 (en) | Arginine compositions for coordinate modification of multiple cardiovascular risk factors | |
| CN1708234A (en) | Antioxidative compositions | |
| JP2020510678A (en) | Methods for improving mitophagy in subjects | |
| US9968629B2 (en) | Product and method for supporting uridine homeostasis | |
| JP5253746B2 (en) | Composition for prevention and / or treatment of lifestyle-related diseases | |
| WO2015085351A1 (en) | Pharmaconutrient composition | |
| US20190321419A1 (en) | Composition | |
| ES2729863T3 (en) | Combinations of a urinary basifying agent and a uric acid crystallization inhibitor for the treatment or prevention of renal lithiasis | |
| JP2006016357A (en) | Anti-fatigue composition | |
| JP2006016358A (en) | Anti-fatigue formulation | |
| US20220143070A1 (en) | Composition for use in the prevention and/or treatment of dysbiosis | |
| JP2006016356A (en) | Composition for hypercholesterolemia | |
| JP2018058831A (en) | Pharmaceutical composition | |
| RU2655803C2 (en) | Pharmaceutical composition for prevention and treatment of atherosclerosis | |
| JP5969206B2 (en) | Antiallergic agent and method for producing the same | |
| JP4786030B2 (en) | Natural killer cell activator | |
| WO2002040014A1 (en) | Fat composition for oral or enteral administration and hexacosanoic acid depressant | |
| JP2008133271A (en) | Composition for preventing and/or treating lifestyle-related diseases | |
| WO2021133950A1 (en) | Polyphenol compositions and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100209 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20100209 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120905 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121102 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121126 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130220 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130304 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130412 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130417 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5253746 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160426 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |